RxDoctor Payments Data

Barbara Davidson, NP

Family · la Jolla, CANPI 1124563226

Payments from drug & device makers

$1,545in general payments, 2019–2025

Across 61 payments — averaging $25.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Coloplast$344
  • Astellas Pharma US Inc$173
  • AbbVie$169
  • Johnson & Johnson$138
  • Progenics Pharmaceuticals, Inc.$125
  • Tolmar, Inc.$110
  • plus $487 from 12 others

What the payments were for

  • Food & beverage$1,47095%
  • Education$755%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,545 in reported general payments places this provider in the 80th percentile of 10,634 family providers in California.

See all family providers in California

Medicare billing

Part B allowed, 2024
$142,797
Medicare patients
483
Services billed
22,835

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron123$85,544
GemtesaVibegron116$83,299
Estradiol307$23,115
EstringEstradiol40$20,988
Methenamine Hippurate84$8,931
IntrarosaPrasterone (Dhea)14$3,630
Trospium Chloride ErTrospium Chloride46$3,522
Trospium Chloride35$1,604
CefuroximeCefuroxime Axetil95$1,316
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst46$1,130
Tamsulosin Hcl53$802
Solifenacin Succinate22$549
Oxybutynin Chloride ErOxybutynin Chloride26$458
Fesoterodine Fumarate ErFesoterodine Fumarate11$208
Cephalexin13$134

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncMyrbetriq$173$85,544123 claims
Sumitomo Pharma America, Inc.Gemtesa$61$83,299116 claims
PfizerEstring$21$20,98840 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 10,634 family providers in California.

Other family in la Jolla

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →